Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005-2008: Is treatment with bisphosphonates an option?

Osteoporosis International

Volumn 25, Issue 5, 2014, Pages 1607-1615

  Lubwama, R ^a   Nguyen, A ^a   Modi, A ^a   Diana, C ^b   Miller, P D ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b IL   (United States)

^c University of Colorado Health Sciences Center   (United States)

Author keywords

Bisphosphonates; Creatinine clearance; Glomerular filtration rate; Osteoporosis; Renal impairment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BONE DENSITY; DIET; DISEASE SEVERITY; FEMALE; FEMUR NECK; GLOMERULUS FILTRATION RATE; HEALTH SURVEY; HIP FRACTURE; HUMAN; KIDNEY FAILURE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MIDDLE AGED; NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SCORING SYSTEM; SPINE FRACTURE; UNITED STATES; BODY MASS; COMPLICATION; CONTRAINDICATIONS; CROSS-SECTIONAL STUDY; OSTEOPOROSIS, POSTMENOPAUSAL; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

AGED; BODY MASS INDEX; BONE DENSITY CONSERVATION AGENTS; CROSS-SECTIONAL STUDIES; DIPHOSPHONATES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; UNITED STATES;

EID: 84899624717     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2645-1     Document Type: Article

References (51)

1. Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ III (2012) The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008. Osteoporos Int 23(3):811-820. doi: 10.1007/s00198-011-1694-y
2. Looker AC, Melton LJ III, Harris TB, Borrud LG, Shepherd JA (2010) Prevalence and trends in low femur bone density among older US adults: NHANES 2005-2006 compared with NHANES III. J Bone Miner Res 25(1):64-71. doi: 10.1359/jbmr.090706
3. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286(22):2815-2822
4. Langsetmo L, Goltzman D, Kovacs CS, Adachi JD, Hanley DA, Kreiger N, Josse R, Papaioannou A, Olszynski WP, Jamal SA (2009) Repeat low-trauma fractures occur frequently among men and women who have osteopenic BMD. J Bone Miner Res 24(9):1515-1522. doi: 10.1359/jbmr.090319
5. National Osteoporosis Foundation (2010) Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, http://www.nof.org/files/nof/public/content/file/344/upload/159.pdf. Accessed 12 Feb 2013
6. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85(11):4118-4124
7. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G (2002) Meta-analysis of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23(4):517-523
8. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350(12):1189-1199. doi: 10.1056/NEJMoa030897
9. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809-1822. doi: 10.1056/NEJMoa067312
10. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799-1809. doi: 10.1056/NEJMoa074941
11. Green JR, Seltenmeyer Y, Jaeggi KA, Widler L (1997) Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 80(5):225-230
12. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT (2012) Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 97(7):2272-2282. doi: 10.1210/jc.2012-1027
13. Miller PD (2011) The kidney and bisphosphonates. Bone 49(1):77-81. doi: 10.1016/j.bone.2010.12.024
14. Sadowski CA, Spencer T, Yuksel N (2011) Use of oral bisphosphonates by older adults with fractures and impaired renal function. Can J Hosp Pharm 64(1):36-41
15. (2012) Fosamax [package insert]. Whitehouse Station, NJ: Merck and Co., Inc.
16. Federal Food and Drug Administration (FDA) (2011) FDA Drug Safety Communication: new contraindication and updated warning on kidney impairment for Reclast (zoledronic acid). U.S. Food and Drug Administration, Department of Health and Human Services, Silver Spring, http://www.fda.gov/Drugs/DrugSafety/ ucm270199.htm. Accessed 15 May 2012
17. (2011) Boniva [package insert]. San Francisco, CA: Genentech, Inc.
18. (2012) Actonel [package insert]. North Norwich, NY: Norwich Pharmaceuticals, Inc.
19. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2009) National Health and Nutrition Examination Survey (NHANES) 2007-2008 Public Data General Release File Documentation. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/ generaldoc-e.htm. Accessed: May 8, 2012
20. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2005) National Health and Nutrition Examination Survey (NHANES) 2005-2006 Public Data General Release File Documentation. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/data/nhanes/nhanes-05-06/ general-data-release-doc-05-06.pdf. Accessed: May 8, 2012
21. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2009) National Health and Nutrition Examination Survey (NHANES): 2005-2006 Data documentation, codebook, and frequencies: dual-energy X-ray absorptiometry - femur bone measurements. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/DXXFEM-D.htm. Accessed 8 May 2012
22. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2009) National Health and Nutrition Examination Survey (NHANES): 2007-2008 Data documentation, codebook, and frequencies: dual-energy X-ray absorptiometry - femur. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/ nchs/nhanes/nhanes2007-2008/DXXFEM-E.htm Accessed 8 May 2012
23. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2010) National Health and Nutrition Examination Survey (NHANES): 2005-2006 Data documentation, codebook, and frequencies: dual-energy X-ray absorptiometry - spine. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/ nchs/nhanes/nhanes2005-2006/DXXSPN-D.htm. Accessed 8 May 2012
24. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2010) National Health and Nutrition Examination Survey (NHANES): 2007-2008 Data documentation, codebook, and frequencies: dual-energy X-ray absorptiometry - spine. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/ nchs/nhanes/nhanes2007-2008/DXXSPN-E.htm. Accessed 8 May 2012
25. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP (1997) Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 12(11):1761-1768. doi: 10.1359/jbmr.1997.12.11.1761
26. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8(5):468-489
27. Kelly TJ (1990) Bone mineral density reference databases for American men and women. J Bone Miner Res 5(Suppl 1):S249
28. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2009) National Health and Nutrition Examination Survey (NHANES): 2007-2008 Data documentation, codebook, and frequencies: urinary albumin and urinary creatinine. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/ nchs/nhanes/nhanes2007-2008/ALB-CR-E.htm Accessed 15 May 2012
29. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2007) National Health and Nutrition Examination Survey (NHANES): 2005-2006 Data documentation, codebook, and frequencies: urinary albumin and urinary creatinine. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/ nchs/nhanes/nhanes2005-2006/ALB-CR-D.htm Accessed 15 May 2012
30. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604-612
31. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139(2):137-147
32. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2 Suppl 1):S1-266
33. Thorp ML, Eastman L, Smith DH, Johnson ES (2006) Managing the burden of chronic kidney disease. Dis Manag 9(2):115-121. doi: 10.1089/dis.2006.9.115
34. World Health Organization (2011) Global Database on Body Mass Index (BMI): BMI Classification. United Nations. http://apps.who.int/bmi/index.jsp? introPage=intro-3.html. Accessed 8 May 2012
35. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2011) Unweighted response rates for National Health and Nutrition Examination Survey (NHANES) 2005-2006 by Age and Gender. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/data/nhanes/response-rates-cps/ RRT0506MF.pdf. Accessed 8 May 2012
36. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (2011) Unweighted response rates for National Health and Nutrition Examination Survey (NHANES) 2007-2008 by age and gender. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/data/nhanes/response-rates-cps/ RRT0708MF.pdf. Accessed 8 May 2012
37. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS) (1996) Analytic and reporting guidelines: the Third National Health and Nutrition Examination Survey, NHANES III (1988-94). U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, http://www.cdc.gov/nchs/data/nhanes/nhanes3/nh3gui.pdf Accessed 8 Nov 2013
38. Miller PD (2007) Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 20(3):186-190. doi: 10.1111/j.1525-139X.2007.00271.x
39. Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR (2007) Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22(4):503-508. doi: 10.1359/jbmr.070112
40. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20(12):2105-2115. doi: 10.1359/jbmr.050817
41. Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, Eriksen EF, Miller PD (2008) Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 74(5):641-648. doi: 10.1038/ki.2008.193
42. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2:138
43. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (113):S1-130. doi: 10.1038/ki.2009.188
44. Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S (2013) Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res 28(10):2049-2059. doi: 10.1002/jbmr.2058
45. Tanko LB, Qin G, Alexandersen P, Bagger YZ, Christiansen C (2005) Effective doses of ibandronate do not influence the 3 years progression of aortic calcification in elderly osteoporotic women. Osteoporos Int 16(2):184-190. doi: 10.1007/s00198-004-1662-x
46. Hill JA, Goldin JG, Gjertson D, Emerick AM, Greaser LD, Yoon HC, Khorrami S, Aziz D, Adams JS (2002) Progression of coronary artery calcification in patients taking alendronate for osteoporosis. Acad Radiol 9(10):1148-1152
47. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756-765. doi: 10.1056/NEJMoa0809493
48. Centers for Disease Control and Prevention (2007) Prevalence of chronic kidney disease and associated risk factors - United States, 1999-2004. MMWR Morb Mortal Wkly Rep 56 (8):161-165
49. Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, Chen SC, Qiu Y, Wang C, Li S, Vassalotti JA, Collins AJ (2008) CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 51(4 Suppl 2):S13-20. doi: 10.1053/j.ajkd.2007.12.016
50. Zimmerman SI, Girman CJ, Buie VC, Chandler J, Hawkes W, Martin A, Holder L, Hebel JR, Sloane PD, Magaziner J (1999) The prevalence of osteoporosis in nursing home residents. Osteoporos Int 9(2):151-157
51. Center for Drug Evaluation and Research (CDER) (2010) Guidance for industry: Pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. U.S. Food and Drug Administration, Department of Health and Human Services, Silver Spring, http://www.fda.gov/Drugs/DrugSafety/ucm270199.htm. Accessed 24 May 2013